OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
-21.81%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.28%
AUM
$222M
AUM Growth
+$222M
(-31%)
Cap. Flow
-$21.7M
Cap. Flow
% of AUM
-9.76%
Top 10 Holdings %
Top 10 Hldgs %
58.76%
Holding
56
New
11
Increased
13
Reduced
17
Closed
9
Top Buys
| 1 |
TELA Bio
TELA
|
$8.18M |
| 2 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$6.7M |
| 3 |
CUTR
Cutera, Inc.
CUTR
|
$5.54M |
| 4 |
UroGen Pharma
URGN
|
$1.96M |
| 5 |
TCON
TRACON Pharmaceuticals, Inc. Common Stock
TCON
|
$1.94M |
Top Sells
| 1 |
CMRX
Chimerix, Inc.
CMRX
|
$9.3M |
| 2 |
BCYC
Bicycle Therapeutics
BCYC
|
$7.68M |
| 3 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$6.78M |
| 4 |
Protagonist Therapeutics
PTGX
|
$5.96M |
| 5 |
Cytokinetics
CYTK
|
$4.09M |
Sector Composition
| 1 | Healthcare | 99.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
4D Molecular Therapeutics
FDMT
$302M
| $2.27M | 1.02% |
325,000
| – | – |
|
27
ProQR Therapeutics
PRQR
$256M
| $2.13M | 0.96% |
2,740,000
+315,000
| +13% | +$245K |
|
|
28
UroGen Pharma
URGN
$896M
| $1.96M | 0.88% |
+238,670
| New | +$1.96M |
|
29
Ginkgo Bioworks
DNA
$671M
| $1.94M | 0.87% |
815,000
-114,780
| -12% | -$273K |
|
30
Verastem
VSTM
$585M
| $1.84M | 0.83% |
1,590,000
-735,000
| -32% | -$852K |
|
31
Larimar Therapeutics
LRMR
$337M
| $1.83M | 0.82% |
932,814
-10,888
| -1% | -$21.3K |
|
32
Hyperfine
HYPR
$88M
| $1.7M | 0.77% |
763,075
| – | – |
|
33
Rhythm Pharmaceuticals
RYTM
$6.75B
| $1.5M | 0.68% |
+362,000
| New | +$1.5M |
|
34
Modular Medical
MODD
$39.7M
| $1.43M | 0.64% |
275,422
+9,322
| +4% | +$48.3K |
|
|
IMPL
35
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
| $1.35M | 0.61% |
+144,642
| New | +$1.35M |
|
|
LENZ
36
LENZ Therapeutics
LENZ
$1.12B
| $1.27M | 0.57% |
460,000
+204,500
| +80% | +$562K |
|
37
Journey Medical
DERM
$169M
| $919K | 0.41% |
245,733
+178,733
| +267% | +$668K |
|
38
Neurogene
NGNE
$284M
| $628K | 0.28% |
610,000
-180,000
| -23% | -$185K |
|
39
MacroGenics
MGNX
$121M
| $614K | 0.28% |
208,300
-168,100
| -45% | -$496K |
|
40
Neuropace
NPCE
$310M
| $446K | 0.2% |
+90,100
| New | +$446K |
|
|
FMTX
41
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $404K | 0.18% |
+58,700
| New | +$404K |
|
|
OPTN
42
DELISTED
OptiNose
OPTN
| $333K | 0.15% |
+90,970
| New | +$333K |
|
|
MRNS
43
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $333K | 0.15% |
+68,900
| New | +$333K |
|
44
Avalo Therapeutics
AVTX
$139M
| $225K | 0.1% |
450,000
-1,004,400
| -69% | -$503K |
|
|
THRX
45
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| $179K | 0.08% |
+32,300
| New | +$179K |
|
|
LUMO
46
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $166K | 0.07% |
+21,520
| New | +$166K |
|
|
BLRX
47
BioLineRX
BLRX
$15.5M
| $21K | 0.01% |
16,667
| – | – |
|
|
AVEO
48
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
| – | – |
-240,000
| Closed | -$1.34M |
|
49
Synlogic
SYBX
$17.4M
| – | – |
-984,200
| Closed | -$2.36M |
|
50
Sutro Biopharma
STRO
$85.6M
| – | – |
-89,980
| Closed | -$740K |
|